Immuno-Oncology

Latest News

kidney cancer
Atezolizumab Falls Short in Pretreated, Advanced Renal Cell Carcinoma

June 17th 2023

The median progression-free survival with atezolizumab to cabozantinib was 10.6 vs 10.8 months with cabozantinib alone.

Blood draws © adobe.stock.com
Repeated Hematologic Evaluations May Not be Necessary for Patients Receiving ICIs

June 7th 2023

Patients With uHCC Who Experience irAEs With Tremelimumab/Durvalumab Achieve Numerical Improvements in OS
Patients With uHCC Who Experience irAEs With Tremelimumab/Durvalumab Achieve Numerical Improvements in OS

June 3rd 2023

FDA
Trifluridine/Tipiracil, Plus Bevacizumab Under Priority Review for Refractory mCRC

April 24th 2023

melanoma
mRNA Vaccine, Plus Pembrolizumab, Minimizes Recurrence Rate in Melanoma

April 22nd 2023

Latest CME Events & Activities

BURST CME™: Utilizing Pathology Reports to Inform Treatment Plans Across GI Cancers

View More

Expert Illustrations & Commentaries™: Exploring the Clinical Rationale for Antagonizing Inflammatory IL-1-beta Signaling in NSCLC

View More

Catching Them Early: A Real-World Case Discussion on the Application of Testing Methodologies to Identify Key Markers Across NSCLC

View More

20th Annual Meeting of the International Society of Gastrointestinal Oncology®

Register Now!

Medical Crossfire®: Diagnostic and Clinical Considerations in Cutaneous T-Cell Lymphoma for the Dermatologist and the Collaborative Cancer Team

View More

2nd Annual International Congress on Pediatric Oncology

View More

2022 BURST Year in Review™: Reflecting on Recent Evidence for Testing in Patients with GI Cancers

View More

2022 BURST Year in Review™: How Has Recent Evidence in Testing Elevated Outcomes in Patients with Lung Cancers

View More

Community Practice Connections™: 23rd Annual International Lung Cancer Congress®

View More

41st Annual CFS®: Innovative Cancer Therapy for Tomorrow®

Register Now!

18th Annual New York Lung Cancers Symposium®

Register Now!

Medical Crossfire: How Should We Leverage Multidisciplinary Lung Cancer Care Teams in Managing Earlier Forms of NSCLC... When the Goal Is Cure?

View More

Virtual Testing Board: Digging Deeper on Your Testing Reports to Elevate Patient Outcomes in Advanced Non–Small Cell Lung Cancer

View More

Medical Crossfire®: Multidisciplinary Strategies to Leverage Clinical Advances on Immune-Based Therapies for Patients with Hepatocellular Carcinoma

View More

2nd Annual Virtual Tumor Board®: Integrating Emerging Testing Methodologies into Optimal Treatment Planning in Gastrointestinal Cancers

View More

Community Practice Connections™: Pathology Oncology Collaborative: Biomarker Testing in an Emerging Era of HER2 Across Breast, GI, and Lung Cancers

View More

Community Practice Connections™: 19th Annual Meeting of the International Society of Gastrointestinal Oncology®

View More

Advancing Precision Care Through Biomarker-Driven Therapy: CEACAM5 as a Therapeutic Target in NSCLC

View More

How CEACAM5 Expression Can Be Measured and Leveraged in NSCLC Care: Current Developments & Future Therapeutic Opportunities

Register Now!

PER's Breast Cancer Symposia in San Antonio

Register Now!

2023 Friday Satellite Symposia: Preceding the 65th ASH Annual Meeting and Exposition

Register Now!

Burst CME™ - Part III – Advent of HER3 Targeted Approaches and Rationale in Breast Cancer Care

View More

Burst CME™ - Part I – Overview of Pathophysiology, Diagnosis, and Management of HER3 Expressing Cancers

View More

Burst CME™ - Part II – Advent of HER3 Targeted Approaches and Rationale in NSCLC Care

View More

Oncology Town Hall™: Primary Investigators Present Key Abstracts in Genitourinary Malignancies from Paris

View More

Show Me Your Care Plan™: Monitoring and Managing Patients With EGFR Exon20 Insertion+ NSCLC

View More

Virtual Tumor Board®: Optimizing HER2 Testing Strategies for Clinical Decision Making in GI Malignancies

View More

Medical Crossfire®: Antibody-Drug Conjugates Coming to Your Oncology Practice Tomorrow

View More

2nd Annual Hawaii Lung: A Multidisciplinary Case-Based Conference™

Register Now!

BURST CME™: Addressing Current Standards and Unmet Needs in Patients with Metastatic Breast Cancer

View More

More News

© 2023 MJH Life Sciences

All rights reserved.